NCT01866267 - Switching Undetectables to Selzentry | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

June 30, 2014

Conditions

Human Immunodeficiency VirusAIDS

Interventions

DRUG

Maraviroc

HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.

Trial Locations (1)

77401

St. Hope Foundation, Inc., Bellaire